1-氨基-N-(氰基甲基)环己烷甲酰胺 | 225122-32-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-氨基-N-(氰基甲基)环己烷甲酰胺
• 英文名称: homocycloleucyl-glycine-nitrile
• 英文别名: homocycloleucyl glycinonitrile；1-amino-cyclohexanecarboxylic acid cyanomethyl amide；1-amino-cyclohexancarboxylic acid cyanomethyl-amide；1-amino-N-cyanomethylcyclohexanecarboxamide；1-amino-N-(cyanomethyl)cyclohexane-1-carboxamide
• CAS: 225122-32-7
• 化学式: C₉H₁₅N₃O
• 分子量: 181.238
• InChiKey: RUWBBBUXZRUXBG-UHFFFAOYSA-N

物化性质

• 沸点：
  413.6±38.0 °C(Predicted)
• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-氨基-N-(氰基甲基)环己烷甲酰胺 在 吡啶 、 铁粉 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 3.0h， 生成 N-(3-fluoro-4-aminobenzoyl)homocycloleucyl-glycinonitrile
  参考文献：
  名称：

  Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors

  摘要：

  Cathepsin K is a major drug target for osteoporosis and related-bone disorders. Using a combination of virtual combinatorial chemistry, QSAR modeling, and molecular docking studies, a series of cathepsin K inhibitors based on N-(functionalized benzoyl)-homocycloleucyl-glycinonitrile scaffold was developed. In order to avoid previous problems of cathepsin K inhibitors associated with lysosomotropism of compounds with basic character that resulted in off-target effects, a weakly- to nonbasic moiety was incorporated into the P3 position. Compounds 5, 6, and 9 were highly selective for cathepsin K when compared with cathepsins L and S, with the K-i values in the 10-30 nM range. The kinetic studies revealed that the new compounds exhibited reversible tight binding to cathepsin K, while the X-ray structural studies showed covalent and noncovalent binding between the nitrile group and the catalytic cysteine (Cys25) site.

  DOI：

  10.1021/acs.jmedchem.5b00746
• 作为产物：
  描述：

  1-(N-叔丁氧羰基氨基)环己烷甲酸 在 甲烷磺酸 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-氨基-N-(氰基甲基)环己烷甲酰胺
  参考文献：
  名称：

  探索组织蛋白酶B S2口袋的荧光特性的新型组织蛋白酶抑制剂：设计，合成和生物学评估

  摘要：

  氟还是氟？基于β，β-二氟环脂族氨基酸，新的二肽腈文库被评估为人组织蛋白酶抑制剂。通过分子建模和NMR研究阐明了氟化面相对于组织蛋白酶B蛋白质结构的方向（见图）。对于（R）配置的体，氟原子被定向到S 2凹穴，而在（S）配置的dis体中，氟化面暴露在溶剂中。

  DOI：

  10.1002/chem.201100113

文献信息

• Facing the gem-Dialkyl Effect in Enzyme Inhibitor Design: Preparation of Homocycloleucine-Based Azadipeptide Nitriles
  作者：Maxim Frizler、Friederike Lohr、Michael Lülsdorff、Michael Gütschow

  DOI：10.1002/chem.201101350

  日期：2011.10.4

  A tough nut to crack: In contrast to azadipeptide nitriles containing a P2 leucine residue, the synthesis of the corresponding homocycloleucine‐based inhibitors was more difficult; possibly due to the gem‐dialkyl effect. A synthetic route to the first homocycloleucine‐derived azadipeptide nitriles as selective and highly potent cathepsin K inhibitors is presented (see scheme).

  一个难以克服的难题：与含有P2亮氨酸残基的氮杂肽腈相比，相应的基于同环亮氨酸的抑制剂的合成更加困难。可能是由于宝石二烷基效应。提出了合成第一个由同环亮氨酸衍生的氮杂二肽腈作为选择性和高效组织蛋白酶K抑制剂的合成途径（参见方案）。
• Fluorescent nitrile-based inhibitors of cysteine cathepsins
  作者：Maxim Frizler、Matthias D. Mertens、Michael Gütschow

  DOI：10.1016/j.bmcl.2012.09.086

  日期：2012.12

  Cysteine cathepsins play an important role in many (patho)physiological conditions. Among them, cathepsins L, S, K and B are subjects of several drug discovery programs. Besides their role as drug targets, cysteine cathepsins are additionally considered to be possible biomarkers for inflammation and cancer. Herein, we describe the design, synthesis, biological evaluation and spectral properties of fluorescently

  半胱氨酸组织蛋白酶在许多（病理）生理状况中起重要作用。其中，组织蛋白酶L，S，K和B是几种药物发现计划的主题。除了它们作为药物靶标的作用外，半胱氨酸组织蛋白酶还被认为是炎症和癌症的可能生物标志物。在这里，我们描述了荧光标记的二肽和氮杂二肽腈的设计，合成，生物学评估和光谱特性。
• Dipeptide nitrile cathepsin K inhibitors
  申请人：——

  公开号：US20010016207A1

  公开（公告）日：2001-08-23

  Dipeptide nitrile Cathepsin K inhibitors of formula I, and pharmaceutically acceptable salts or esters thereof 1 In which R 1 and R 2 are independently H or C 1 -C 7 lower alkyl, or R 1 and R 2 together with the carbon atom to which they are attached form a C 3 -C 8 cycloalkyl ring, and Het is an optionally substituted nitrogen-containing heterocyclic substituent, are provided, useful e.g. for therapeutic or prophylactic treatment of a disease or medical condition in which cathepsin K is implicated.

  提供了公式I的二肽基腈基Cathepsin K抑制剂，以及其药用可接受的盐或酯。其中R1和R2独立地是H或C1-C7较低的烷基，或者R1和R2与它们附着的碳原子一起形成一个C3-C8环烷基环，Het是一个可选择地取代的含氮杂环取代基，可用于治疗或预防与Cathepsin K有关的疾病或医疗状况。
• Dipeptide nitriles
  申请人：Novartis AG

  公开号：US06353017B1

  公开（公告）日：2002-03-05

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽腈可作为半胱氨酸蛋白酶抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗依赖于半胱氨酸蛋白酶的疾病和症状，包括炎症、类风湿关节炎、骨关节炎、骨质疏松、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉粥样硬化（包括动脉粥样硬化斑块破裂和不稳定）。特定的二肽腈化合物为公式I的化合物，或其生理上可接受和可裂解的酯或盐，其中：符号如定义。特别是发现通过适当选择基团R、R2、R3、R4、R5、X1、Y和L，可以改变化合物作为各种半胱氨酸蛋白酶类型抑制剂的相对选择性，例如半胱氨酸蛋白酶B、K、L和S，可改变，例如获得选择性抑制特定蛋白酶类型或蛋白酶类型组合的抑制剂。
• Novel compounds and compositions as protease inhibitors
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：US20020086996A1

  公开（公告）日：2002-07-04

  The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新颖的N-氰甲基酰胺，它们是半胱氨酸蛋白酶抑制剂，以及它们的药用盐和N-氧化物，它们作为治疗剂的用途以及它们的制备方法。